Skip to main content
Premium Trial:

Request an Annual Quote

People In the News: Nov 29, 2013

NEW YORK (GenomeWeb News) – The genome editing firm Editas Medicine said this week in connection with its $43 million raise it has named a leadership team and board of directors.

The company’s leadership team includes Kevin Bitterman as interim president, Alexandra Glucksmann as interim chief operating officer and Lou Tartaglia as interim chief scientific officer. Bitterman is a principal at Polaris Ventures; Glucksmann was a founding employee and senior VP of R&D at Cerulean Pharma; and Tartaglia is a partner with Third Rock Ventures.

The company’s board of directors includes Alexis Borisy, a partner with Third Rock; Douglas Cole, a general partner with Flagship Ventures; and Terry McGuire, co-founder and general partner at Polaris Partners.

The Danish company Anapa Biotech (formerly Quantibact) this week said it has appointed Soren Echwald to be company CEO. He replaces Palle Schelde, who is leaving the company for a position with a biotech company. Echwald formerly was VP of business development at Exiqon.

Response Genetics’ stockholders last week reelected the company’s board of directors until the company’s next stockholder meeting.

The board includes Thomas Bologna; Kirk Calhoun; Sam Chawla; David Schreiber; Michael Serrruya; Richard van den Broek; and David Wurzer.

Genetic Technologies Limited said today Tommaso Bonvino and Benjamin Silluzio have stepped down from the company’s board of directors, and that Ian McKenzie and Graham Leonard have been elected to the board.

Bonvino and Silluzio withdrew their nominations for election to the board before the company’s annual shareholder meeting today.

McKenzie has worked at Massachusetts General Hospital and the Jackson Laboratory, he was a founding director of the Austin Research Institute at Melbourne University, and he has recently worked as a consultant for several biotech companies.

Leonard has worked at a chartered accountant and barrister in Australia, and he has been a division general manager with Nylex, and chief operating officer and finance director of the Australian subsidiary of The Thomson Corporation.

Proteome Sciences said this week it has appointed Premal Shah vice president of business development.

Shah was previously director of business development at Genomic Health

Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.